Provider: Wright Reports
Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Actelion Ltd Lowers FY 2012 Revenue Guidance-Conference Call
Actelion Ltd announced that for fiscal 2012, it expects product sales on a local currency basis to decline in the low-single-digit range compared to the mid- to low-single-digit range communicated earlier in the year, in February. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.72 billion for fiscal 2012.
Latest Developments for Actelion Ltd
- Actelion Ltd Receives US FDA Approval Of Opsumit For The Treatment Of Pulmonary Arterial Hypertension
- Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics
- Actelion Ltd Raises FY 2013 EPS Guidance; Updates FY 2014 EPS Guidance; Lowers FY 2015 EPS Guidance-DJ
- Actelion Ltd Issues FY 2013 EPS Guidance Above Analysts' Estimates; Comments On FY 2014 And FY 2015 EPS Guidance-Conference Call
- Share this
- Digg this